Article
A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma.
Oncotarget - 16 May 2017
Goncalves Priscila H, Heilbrun Lance K, Barrett Michael T, Kummar Shivaani, Hansen Aaron R, Siu Lillian L, Piekarz Richard L, Sukari Ammar W, Chao Joseph, Pilat Mary Jo, Smith Daryn W, Casetta Lindsay, Boerner Scott A, Chen Alice, Lenkiewicz Elizabeth, Malasi Smriti, LoRusso Patricia M
Abstract excerpt
PURPOSE: Vorinostat is a histone deacetylase inhibitor (HDACi). Based on a confirmed partial response (PR) in an adenoid cystic carcinoma (ACC) patient treated with vorinostat in a prior phase 1 trial, we initiated this phase 2 trial. METHODS: Vorinostat was administered orally 400 mg daily, 28 day cycles. The primary objective was to evaluate response rate (RR). Exploratory studies included whole exome...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.